Physician profile
Jackson E Hatfield
NPI 1316238744
$7,573.75
in general payments reported to CMS, 2019-2025
40 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $253 · 2021: $912 · 2022: $1,050 · 2023: $1,270 · 2024: $1,490 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,518.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,094.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $918.01 | 2021-2025 | |
| Pfizer INC. | $736.34 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $657.71 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $558.02 | 2021-2025 | |
| Lilly USA, LLC | $547.13 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $544.92 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $471.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $277.75 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $232.04 | 2019-2024 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $172.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $163.40 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Exact Sciences Corporation | $134.48 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $93.46 | 2019 | |
| Allergan, INC. | $78.80 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Hatfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.